Tradewinds LLC. Sells 279 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Tradewinds LLC. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 5,186 shares of the biopharmaceutical company’s stock after selling 279 shares during the quarter. Tradewinds LLC.’s holdings in Gilead Sciences were worth $435,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of GILD. nVerses Capital LLC bought a new position in Gilead Sciences during the third quarter valued at $25,000. Valued Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. CarsonAllaria Wealth Management Ltd. grew its holdings in Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences in the 2nd quarter worth about $33,000. Finally, Cedar Wealth Management LLC lifted its stake in Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on GILD. The Goldman Sachs Group increased their price target on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Wells Fargo & Company increased their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a report on Monday. Finally, Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $94.00.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,947 shares of company stock worth $4,968,674. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $88.63 on Thursday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The business’s fifty day simple moving average is $87.15 and its 200-day simple moving average is $76.52. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $110.46 billion, a PE ratio of 984.78, a PEG ratio of 2.72 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.29 EPS. Analysts expect that Gilead Sciences, Inc. will post 4.38 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.48%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.